Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026
Same author

Applications of transcranial focused ultrasound for primary brain tumors.

Neuro-oncology advances·2026
Same author

Spatial Regulation of CAR Signaling Enables Logic-Gated Activity.

bioRxiv : the preprint server for biology·2026
Same author

Preoperative opioid use and postoperative outcomes after primary percutaneous glycerin rhizotomy for trigeminal neuralgia.

Clinical neurology and neurosurgery·2026
Same author

Neurosurgical and prehospital timing in severe traumatic brain injury: Insights from the prospective Resuscitation Outcomes Consortium hypertonic saline trial.

The journal of trauma and acute care surgery·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonists and Outcomes After Intracerebral Hemorrhage in Patients With Type 2 Diabetes: A Propensity-Matched Cohort Study.

Neurosurgery·2026

Related Experiment Video

Updated: Sep 18, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.8K

GLUT1 as a Potential Therapeutic Target in Glioblastoma.

Fnu Ruchika1, Sanika Suvarnapathaki1, Antolin Serrano-Farias1

  • 1Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.

Brain Sciences
|June 26, 2025
PubMed
Summary

Targeting glucose transporter 1 (GLUT1) in glioblastoma (GBM) offers therapeutic potential. Inhibiting GLUT1 may reduce tumor metabolism and improve survival, making it a promising biomarker and drug target for this aggressive brain cancer.

Keywords:
GLUT1Warburg effectglioblastomahypoxia

More Related Videos

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

3.6K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

Related Experiment Videos

Last Updated: Sep 18, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.8K
Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

3.6K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

Area of Science:

  • Neuro-oncology
  • Cancer Metabolism
  • Molecular Biology

Background:

  • Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
  • GBM cells exhibit the Warburg effect, a metabolic shift favoring glycolysis.
  • Glucose transporter 1 (GLUT1) is overexpressed in GBM and drives tumor progression.

Purpose of the Study:

  • To review the role of GLUT1 in glioblastoma biology.
  • To highlight GLUT1 as a potential therapeutic target and prognostic biomarker.
  • To discuss the impact of targeting GLUT1 on GBM metabolism and patient outcomes.

Main Methods:

  • Literature review of preclinical and clinical studies on GLUT1 in GBM.
  • Analysis of the molecular pathways regulating GLUT1 expression (e.g., HIF-1α, c-Myc).
  • Evaluation of the efficacy of GLUT1 inhibitors (e.g., WZB117, BAY-876) in vitro and in vivo.

Main Results:

  • GLUT1 overexpression is linked to tumor aggressiveness and poor prognosis in GBM.
  • Targeting GLUT1 with inhibitors impairs GBM cell metabolism and viability.
  • Preclinical studies demonstrate improved survival with GLUT1 inhibition in GBM models.
  • Elevated GLUT1 expression serves as a negative prognostic marker.

Conclusions:

  • GLUT1 plays a critical role in GBM pathogenesis and metabolic adaptation.
  • Targeting GLUT1 presents a promising therapeutic strategy for glioblastoma.
  • GLUT1 is a valuable biomarker for predicting GBM patient outcomes.